6-MAPB
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
6-MAPB (1-(benzofuran-6-yl)-N-methylpropan-2-amine) is an entactogen of the benzofuran family which is structurally related to 6-APB and MDMA. It is known to be a serotonin releasing agent and, unlike MDMA, a potent serotonin 5-HT 1B receptor agonist. The drug is not known to have been widely sold as a "designer drug" but has been detected in analytical samples taken from individuals hospitalised after using drug combinations that included other benzofuran derivatives. 6-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014. It was banned in the United Kingdom in June 2013, along with 9 other related compounds which were thought to produce similar effects.
6-MAPB (1-(benzofuran-6-yl)-N-methylpropan-2-amine) is an entactogen of the benzofuran family which is structurally related to 6-APB and MDMA. It is known to be a serotonin releasing agent and, unlike MDMA, a potent serotonin 5-HT 1B receptor agonist. The drug is not known to have been widely sold as a "designer drug" but has been detected in analytical samples taken from individuals hospitalised after using drug combinations that included other benzofuran derivatives. 6-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014. It was banned in the United Kingdom in June 2013, along with 9 other related compounds which were thought to produce similar effects.
Interactions
See also
Substituted benzofuran 5-MAPB, 5-APB, and 6-APB BK-5-MAPB and BK-6-MAPB TACT411 and TACT833
References
External links
6-MAPB - Isomer Design
Text derived from https://en.wikipedia.org/w/index.php?oldid=1358904052 under CC BY-SA 4.0; modifications have been made.